ORPHAZYME A/S - ADR (ORPH) Stock Price & Overview
NASDAQ:ORPH
Current stock price
The current stock price of ORPH is 0.87 null. Today ORPH is down by -2.25%. In the past month the price decreased by -28.1%. In the past year, price decreased by -89.88%.
ORPH Key Statistics
- Market Cap
- 30.722M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.79
- Dividend Yield
- N/A
ORPH Stock Performance
ORPH Stock Chart
ORPH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ORPH. When comparing the yearly performance of all stocks, ORPH is a bad performer in the overall market: 99.41% of all stocks are doing better.
ORPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ORPH. ORPH may be in some trouble as it scores bad on both profitability and health.
ORPH Earnings
ORPH Forecast & Estimates
9 analysts have analysed ORPH and the average price target is 15.81 null. This implies a price increase of 1717.72% is expected in the next year compared to the current price of 0.87.
ORPH Groups
Sector & Classification
ORPH Financial Highlights
Over the last trailing twelve months ORPH reported a non-GAAP Earnings per Share(EPS) of -3.79. The EPS decreased by -37.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -6429.52% | ||
| ROA | -197.56% | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
ORPH Ownership
ORPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 370.255B | ||
| AMGN | AMGEN INC | 15.28 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.43 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ORPH
Company Profile
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
Company Info
IPO: 2017-11-17
ORPHAZYME A/S - ADR
Ole Maaloees Vej 3, Copenhagen N
KOEBENHAVN DK-2200 DK
CEO: Anders Vadsholt
Employees: 180
Phone: 4539178272.0
ORPHAZYME A/S - ADR / ORPH FAQ
Can you describe the business of ORPHAZYME A/S - ADR?
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
Can you provide the latest stock price for ORPHAZYME A/S - ADR?
The current stock price of ORPH is 0.87 null. The price decreased by -2.25% in the last trading session.
What is the dividend status of ORPHAZYME A/S - ADR?
ORPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of ORPH stock?
ORPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is ORPHAZYME A/S - ADR (ORPH) stock traded?
ORPH stock is listed on the Nasdaq exchange.
What sector and industry does ORPHAZYME A/S - ADR belong to?
ORPHAZYME A/S - ADR (ORPH) operates in the Health Care sector and the Biotechnology industry.